By A. Kleemann, J. Engel
Pharmaceutical elements is designed to be an entire reference consultant to each pharmaceutical compound of value, offering a wealth of knowledge now not present in the other source including:
- precise artificial path together with intermediates
- alternate names and advertising and marketing facts
- patent details
It is vital as a primary aspect of reference not just for experts in drug chemistry but in addition for a person interested by the selling, sale and use of prescription drugs and pharmaceutical ingredients.
The description of every compound includes:
- Chemical constitution
- Graphical illustration of man-made course together with intermediates
- Nomenclature: resort general, trivial names, synonyms, CAS quantity
- ATC codes
- scientific applications/Therapeutic class
- Toxicological information
- Patent quantity, starting place, holder and expiry date
- advertisement info
- Bibliographic details together with CASSI codes
Of additional price are the indexes of compound sessions, intermediates, exchange names and enzymes, microorganisms, crops and animal tissues.
Read or Download Pharmaceutical Substances. Syntheses, Patents, Applications PDF
Similar pharmacy books
Free Energy Calculations in Rational Drug Design
Loose power calculations symbolize the main exact computational procedure on hand for predicting enzyme inhibitor binding affinities. Advances in machine strength within the Nineties enabled the sensible program of those calculations in cause drug layout. This ebook represents the 1st complete overview of this becoming quarter of analysis and covers the fundamental conception underlying the strategy, quite a few cutting-edge techniques designed to enhance throughput and dozen examples in which loose power calculations have been used to layout and review capability drug applicants.
The School of Pharmacy, University of London. Medicines, Science and Society, 1842–2012
The college of Pharmacy, collage of London: medications, technology and Society, 1842-2012 represents the wealthy historical past of the college of London institution of Pharmacy via a number of colour images, vital advances within the pharmacy career, cultural milestones, biographies and extra. Written in an interesting and authoritative type, this publication depicts the chronological heritage of the varsity from its institution in 1842 to the current day with a nod towards its aspirations for the long run.
This quantity offers the reader with contemporary advances within the fields of molecular toxinology, the biotechnological purposes of venom pollutants, and antivenom construction. The content material of the twenty chapters of Venom Genomics and Proteomics illustrates not just the big development made because the implementation of omics applied sciences within the box of toxinology, yet one additionally realizes the line nonetheless forward to arrive a holistic view of venomous structures.
Pharmaceutical Process Scale-Up
Targeting medical and sensible elements of method scale-up, this source information the speculation and perform of moving pharmaceutical methods from laboratory scale to the pilot plant and creation scale. It covers parenteral and nonparenterel drinks and semi-solids, items derived from biotechnology, dry mixing and powder dealing with, granulation and drying, fluid mattress functions, compaction and tableting, and movie coating and regulatory requisites for scale-up and postapproval adjustments.
Extra resources for Pharmaceutical Substances. Syntheses, Patents, Applications
Example text
1977; prior. 1976). pharmaceutical formulation: JP-appl. 78 136 512 (Chugai; appl. 1977). 1979; J-prior. 1977) use as anti-inflammatory: FX 2 389 377 (J. Brohult, appl. 1977). Formulation(s): amp. 002 mg; cps. 0025 mg, 1 mg; inj. ) 55 A 56 Alfaxalone ride etherote alfaxalone (I) lead tetraacetate Alfodolane ocetote (4. HBr. CH,OH H3C4&, bromine patossium acetate acetone Reference(s): DE 2 030 402 (Glaxo; appl. 1970; GB-prior. 1970). ZA 703 861 (Glaxo; appl. 1970; GB-prior. 1969) (alternative synthesis).
1980; GB-prior. 1974). GB 1 523 865 (Burroughs Wellcome; GB-prior. 1974). c GB 1 567 671 (Wellcome; appl. 1977; USA-prior. 1976). Matsumoto, H. : Chem. Pharm. Bull. (CPBTAL) 36, 1153 (1988). f EP709 385 (Roche; appl. 1995; USA-prior. 1995). 1990; DK-prior. 1989). alternative synthesis via formylguanine: WO 9 507 281 (Recordati; appl. 1994; I-prior. 1993) synthesis using 1,3-dioxolane: US 5 567 816 (Syntex; appl. 1995; USA-prior. 1994). improved procedures: DE 19 536 164 (Boehringcr Ingelheim; D-prior.
500 pglml; inj. sol. I mgl2 ml, 5 mg/lO ml; intensive care inj. 46 (+)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazalinyl)methylamino]propyl]tetrahydro-2-furancarboxamide monohydrochloride RN: 81403-68-1 MF: C19H27N504. 92 OHCaO-CH~ ,OHC~~'~~: , . 1982; F-prior. 1978). DE 290 445 (Synthelabo; appl. 1979; F-prior. 1978). M. : J. Med. Chem. (JMCMAR) 29, 19 (1986). : J. Med. Chem. (JMCMAR) 20, 146 (1977). Formulation(s): tabl. 47 EINECS: 209-869-2 Alibendol 16-dehydroprogesterone 16u, 17a-dihydroxyprogesterone I A (I) -------------, acetophenone 1 Algestone acetophenide I Reference(s): DE 1 125 423 ( O h Mathieson; appl.